Conditionally replicating adenovirus therapy utilizing bone sialoprotein promoter (Ad-BSP-E1a) in an in vivo study of treating androgen-independent intraosseous prostate cancer
| Autor: | Kenneth S. Koeneman, Melissa Thompson, Yingming Li, Michael Kacka, Jer Tsong Hsieh |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Bone sialoprotein
Male Urology Genetic enhancement Genetic Vectors Mice Nude Bone Neoplasms Adenocarcinoma Adenoviridae Prostate cancer Mice fluids and secretions stomatognathic system In vivo Cell Line Tumor medicine Animals Humans Promoter Regions Genetic biology Cell growth business.industry Androgen independent Prostatic Neoplasms Genetic Therapy medicine.disease Xenograft Model Antitumor Assays In vitro Clinical trial Oncology biology.protein Cancer research Osteopontin Adenovirus E1A Proteins business |
| Zdroj: | Urologic oncology. 29(6) |
| ISSN: | 1873-2496 |
| Popis: | Background Adenoviral based gene therapy has been used in clinical trials in control of advanced prostate cancer. In this study, a promising conditionally replicating adenovirus (CRAd) driven by a tissue specific bone sialoprotein promoter in controlling prostate cancer both in vitro and in vivo is demonstrated. Methods C4-2B, an androgen-independent prostate cancer cell line, was treated with PBS, Ad-BSP-TK, or the Ad-BSP-E1a in vitro, and in subcutaneous and intraosseous xenographs. Cell proliferation, PSA level in condition medium, tumor volume, and/or serum PSA were followed. Results The growth of C4-2B and the PSA production was dramatically suppressed by Ad-BSP-E1a at very low dosage (0.3 MOI) compared with PBS and Ad-BSP-TK treatment in vitro. In the subcutaneous model, the tumor volume was significantly lower statistically in the Ad-BSP-E1a treated group than the Ad-BSP-TK control group ( P = 0.02). In the intraosseous model, the mice treated in the Ad-BSP-E1a treatment group demonstrated a significant lower PSA compared to that in the control group ( P Conclusions The CRAd Ad-BSP-E1a revealed potential in treating prostate cancer in this model system. Using viral or none-viral mediated gene therapy to treat prostate carcinoma continues to be a potential avenue to treat afflicted men with prostate cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect